TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Repetition of Nonsense Words Subtests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expressive Vocabulary Test (EVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aqueous levels of antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of Procedure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: total conjunctival symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score-28 (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Symptom Inventory (FSI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: number of live births after 28 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: bleeding post-exodontic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in permeability of the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in spasticity: MSSS-88
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in spasticity: Modified Tardieu scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Nominal Change From Baseline in Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment Based Therapeutic Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grouped Change From Baseline in Erythema Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Basal blood glucose value before starting TPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of severe hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Generic Mental Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vibratory sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Over Time With Positive Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to First Positive Parasitemia Based on Quantitative Polymerase Chain Reaction (qPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Symptoms of Malaria Assessed Using Malaria Clinical Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory block at 12th thoracic dermatome or above
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful conduct of the lower limb surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: changes in hydroxytyrosol generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Autologous tumor cell cytotoxicity lymphocyte (CTL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine production (IFN gamma, IL-10, IL-2) by RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity as assessed by NCI Common Terminology Criteria (CTC)
Endpoint domain: Adverse events/effects
Primary endpoint: Level of methylated DNA in circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of haemoglobin in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Onset of Warming Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Warming Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warming Sensation Intensity at Pre-Dose and 60 Sec (Seconds) Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levator ani muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Silt-lamp examination of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of clinically significant PSAS requiring IV pethidine
Endpoint domain: Adverse events/effects
Primary endpoint: Average use of the Adaptive Servo Ventilation device per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Optimal dose of PulmoBind for lung imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feasibility of comprehensive chemical gustometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural-Related Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: development of transglutaminase antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visible presence of blood around the emergency site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved HIV Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: change in detrusor pressure post-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total Free Thiols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Expression Level of EGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Expression Level of Cyclin D1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Expression Level of Phosphorylated EGFR (pEGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratidal compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Decisional Conflict Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Comprehension of Treatment Options Score assessed by Interview
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Comprehension of Side Effects Score assessed by Interview
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Early Bactericidal Activity (EBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-requiring ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Change in Mini-Mental test examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Responders to Varenicline Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of angiomyolipomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Decreased Gene Expression of CYP19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Vaginal Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sentinel lymph node biopsy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary Tract Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Delirium/ coma free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving hemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of adverse events including serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) part III scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EuroQol 5 Dimensions 5 Level (EQ-5D-5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak flow and asthma symptom diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Hemorrhagic Transformation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma hydrocodone and acetaminophen concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: characteristic metabolic pattern of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Respiratory rate per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anti-glycoprotein (gE) Specific Antibody (Ab) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of gE (Glycoprotein)-Specific Cluster of Differentiation (CD4) (2+) T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Complete Response (pCR) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Direction Discrimination Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direction Integration Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity for Direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast Sensitivity for Static Orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' Drop-out Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in ADHD RS-IV total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized Levodopa AUC(0-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized L-DOPA Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: L-DOPA Terminal Phase Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPS-NI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in % kilocalories/day obtained orally
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of postoperative residual neuromuscular blockade (rNMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recovery time-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative dosage of catecholamine application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Immune Reactions to LOAd703 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MACCE at 12-months
Endpoint domain: Mortality/survival
Primary endpoint: urinary concentration of nerve growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Event-Related Field (ERF) Amplitude and Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional gray and white matter brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean area under the plasma-concentration time curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to maximum observed concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of negative impact on life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Home Exercise Adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of intravascular injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Parent Reported Patient Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of sessions of practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of sessions of practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of minutes of practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with pancreatic necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion-weighted coefficient imaging of testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectroscopy of the testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Assessment of Recovery (PGAR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return to Work/School/ADLs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2*MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious COVID-19 infection
Endpoint domain: Mortality/survival
Primary endpoint: Severe infection (requiring admission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: COVID-19 related death
Endpoint domain: Mortality/survival
Primary endpoint: Change in infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of time spent awake
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Effectiveness of tranexamic acid in reducing periorbital hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in perception of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perception of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the feeling of swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Able to Administer a Full Dose of Erenumab in Home-use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis of non ST segment elevation acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Step down of medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity: Percentage of True Positive Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity: Percentage of True Negative Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Deviation Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of New or Worsening Vertebral Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Plasma Concentration Following Drug Administration at Steady State (Cmin,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta 1 power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the One Repetition Maximum Isometric Lingual Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone speed of sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence Impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in the reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in the central blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms of Anxiety and Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood and urine safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease and comfort of clean intermittent self-catheterization
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of bladder drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and Tolerability of SER-287
Endpoint domain: Adverse events/effects
Primary endpoint: Composition of the Intestinal Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Engraftment of SER-287 Bacteria in All Treatment Arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-infectives concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seizure Frequency Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II Dose (RP2D) of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROBE score variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transmission of pathologic bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in frequency of regulatory and effector B cell subset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of knee uptake of 99mTc-EC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Voice Handicap Index (VHI)-10 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in jitter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in shimmer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Unbound AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life of Anemic Participants Using Short Form 36 (SF-36) Questionnaire 3-4 Weeks After Start of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fatigue Severity Score 3-4 Weeks After Start of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Post-dural puncture headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy and precision of TempTraq thermometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes